BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS
Conditions
Brief summary
Proportion of participants who achieve a cCR after 3 TAGVEN cycles.
Detailed description
- Objective response rate including cCR and partial remission after 3 TAGVEN cycles - Safety profile of the tagraxofusp and venetoclax combination - Proportion of patients with MRD - Negative responses measured by flow cytometry - Progression-free Survival - Duration of response - Overall Survival - Proportion of patients bridged to allogeneic stem cell transplantation - Possible predictors of response with respect to cytogenetics and mutational status
Interventions
DRUGVenetoclax
Sponsors
French Innovative Leukemia Organization
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of participants who achieve a cCR after 3 TAGVEN cycles. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Objective response rate including cCR and partial remission after 3 TAGVEN cycles - Safety profile of the tagraxofusp and venetoclax combination - Proportion of patients with MRD - Negative responses measured by flow cytometry - Progression-free Survival - Duration of response - Overall Survival - Proportion of patients bridged to allogeneic stem cell transplantation - Possible predictors of response with respect to cytogenetics and mutational status | — |
Countries
France
Outcome results
None listed